隶属于 Agenus, Inc.
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
已完成
3
75.0%
招募中
1
25.0%
暂无批准数据
- C-Further, an international pediatric oncology consortium, unveiled its first two therapeutic programs targeting childhood cancers including Ewing sarcoma, bone sarcoma, medulloblastoma, and acute myeloid leukemia with $40 million in initial funding. - CF-012 represents a potential first-in-class ETV6 inhibitor for Ewing sarcoma developed in collaboration with UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute, and Mass General Brigham. - CF-033 is an allogeneic PRAME-targeted iNKT cell therapy developed with MiNK Therapeutics that requires no HLA matching or toxic lymphodepletion, designed for multiple pediatric cancers. - MiNK Therapeutics will receive approximately $1.1 million in non-dilutive funding plus meaningful double-digit commercial revenue participation for the PRAME-targeted program.
- MiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis. - The findings provide direct human tissue evidence supporting a mechanistic role for iNKT insufficiency in advanced IPF, potentially contributing to persistent inflammation and progressive fibrotic remodeling. - This research expands MiNK's iNKT platform into chronic fibrotic lung disease, complementing ongoing development programs in oncology, GVHD, and severe pulmonary inflammation. - IPF affects approximately 100,000 patients in the United States with a median survival of 3-5 years, representing a substantial unmet medical need with no approved treatments capable of reversing fibrosis.
- MiNK Therapeutics announced the initiation of a Phase 1 clinical trial evaluating agenT-797, an off-the-shelf allogeneic iNKT cell therapy, in patients undergoing stem cell transplantation to prevent graft-versus-host disease. - The investigator-sponsored trial will assess safety, tolerability, and preliminary efficacy of agenT-797 in reducing GvHD, relapse, and post-transplant complications in patients with high-risk leukemias and blood cancers. - The therapy represents a novel approach that requires no lymphodepletion or HLA matching, potentially offering improved outcomes for transplant patients while addressing a complication affecting up to half of stem cell transplant recipients. - The study is supported by complementary funding from an NIH STTR grant and the Mary Gooze Clinical Trial Award, enabling simultaneous translational and clinical research.
- MiNK Therapeutics published preclinical data showing MiNK-215, an IL-15 enhanced FAP-targeting CAR-iNKT therapy, successfully eliminates tumor-protective fibroblasts and enables immune cell infiltration in solid tumors. - The therapy demonstrated potent anti-tumor activity in lung and MSS colorectal cancer models by remodeling the tumor microenvironment and activating multiple immune pathways including dendritic cells and macrophages. - As an off-the-shelf allogeneic therapy, MiNK-215 offers a scalable treatment approach for patients with solid tumors that have been unresponsive to checkpoint inhibitors and other immunotherapies.
- MiNK Therapeutics will present late-breaking Phase 1 data showing durable clinical activity of AgenT-797, an allogeneic iNKT cell therapy, in patients with advanced solid tumors at SITC 2025. - AgenT-797 is an off-the-shelf, cryopreserved iNKT cell therapy designed to reprogram the immune system and overcome resistance to conventional immunotherapies. - The updated Phase 1 findings will highlight safety and efficacy results from the ongoing study, with presentation scheduled for November 8, 2025. - MiNK's proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse through immune reconstitution therapies.
- MiNK Therapeutics has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases to accelerate their invariant natural killer T (iNKT) cell therapy pipeline toward pivotal development. - Dr. Hammond's clinical work has demonstrated meaningful survival benefit and reduced infectious complications in severe acute lung injury and life-threatening hypoxemic pneumonia using MiNK's agenT-797 therapy. - The company is preparing to launch a grant-funded clinical trial in graft-versus-host disease (GVHD) and advance a late-stage trial in severe pulmonary disease. - agenT-797 is an off-the-shelf allogeneic iNKT cell therapy that combines cytotoxic capabilities of NK cells with T-cell-like antigen recognition and memory.
- MiNK Therapeutics achieved a complete clinical response in a 49-year-old man with metastatic testicular cancer using invariant natural killer T cell therapy, with durable remission published in Nature's Oncogene. - The company reported greater than 40% tumor shrinkage in a refractory gastric cancer patient, prompting an ongoing Phase II trial at Memorial Sloan Kettering Cancer Center with top-line data expected by end of 2025. - MiNK reduced Q2 operating cash burn by over 30% year-over-year and raised an additional $13 million through equity sales, extending cash runway through mid-2026. - The company positions itself as the most clinically advanced in off-the-shelf invariant natural killer T cell industrialization, with upcoming catalysts including GvHD Phase I trial initiation and MiNK-215 engineered iNKT program advancement.
- Agenus announced the launch of the BATTMAN Phase 3 trial evaluating botensilimab (BOT) and balstilimab (BAL) combination therapy in metastatic microsatellite stable colorectal cancer patients who have exhausted treatment options. - Clinical data showed BOT demonstrated a 42% two-year survival rate and 21-month median overall survival in late-stage MSS colorectal cancer patients, significantly outperforming traditional chemotherapy's 10-14 month survival. - The combination therapy showed promising results across multiple cancer types, with neoadjuvant trials reporting 70% pathological complete response in MSI-H tumors and 20% in MSS tumors. - Company executives called for regulatory reform to accelerate patient access to promising therapies, citing the urgent need for FDA approval processes to match the pace of scientific advancement.
- MiNK Therapeutics reported a complete and lasting remission in a patient with advanced testicular cancer using their experimental iNKT cell therapy agenT-797, published in Nature's Oncogene. - The patient, who had failed multiple standard treatments including chemotherapy and checkpoint inhibitors, achieved full remission with a single infusion combined with nivolumab and remained disease-free for over two years. - The breakthrough demonstrates the potential of allogeneic cell therapies against solid tumors, with agenT-797 being an "off-the-shelf" treatment that doesn't require patient-specific customization. - MiNK's stock surged over 640% following the announcement, highlighting investor confidence in the company's invariant natural killer T cell platform technology.
- MiNK Therapeutics published a landmark case in Nature's Oncogene showing complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer following treatment with agenT-797, their allogeneic iNKT cell therapy. - The patient achieved complete clinical, radiologic, and biochemical remission with no evidence of disease over two years after receiving a single infusion of agenT-797 alongside nivolumab, despite having failed multiple prior therapies including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors. - The treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease, and donor iNKT cells remained detectable up to six months post-infusion. - Additional clinical evidence from MiNK's Phase 2 gastric cancer trial demonstrates immune activation, increased tumor infiltration, and extended survival beyond 12 months in several patients previously refractory to checkpoint inhibitors.
